| Pembrolizumab plus axitinib versus sunitinib for advanced renal-cell carcinoma BI Rini, ER Plimack, V Stus, R Gafanov, R Hawkins, D Nosov, F Pouliot, ... New England Journal of Medicine 380 (12), 1116-1127, 2019 | 3039 | 2019 |
| Durvalumab plus platinum–etoposide versus platinum–etoposide in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): a randomised, controlled, open-label … L Paz-Ares, M Dvorkin, Y Chen, N Reinmuth, K Hotta, D Trukhin, ... The Lancet 394 (10212), 1929-1939, 2019 | 1710 | 2019 |
| Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for previously untreated locally recurrent inoperable or metastatic triple-negative breast cancer (KEYNOTE-355 … J Cortes, DW Cescon, HS Rugo, Z Nowecki, SA Im, MM Yusof, C Gallardo, ... The Lancet 396 (10265), 1817-1828, 2020 | 1373 | 2020 |
| Durvalumab, with or without tremelimumab, plus platinum–etoposide versus platinum–etoposide alone in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN … JW Goldman, M Dvorkin, Y Chen, N Reinmuth, K Hotta, D Trukhin, ... The Lancet Oncology 22 (1), 51-65, 2021 | 499 | 2021 |
| Durvalumab with or without tremelimumab in combination with chemotherapy as first-line therapy for metastatic non–small-cell lung cancer: the phase III POSEIDON study ML Johnson, BC Cho, A Luft, J Alatorre-Alexander, SL Geater, ... Journal of Clinical Oncology 41 (6), 1213-1227, 2023 | 230 | 2023 |
| Pembrolizumab plus ipilimumab or placebo for metastatic non–small-cell lung cancer with PD-L1 tumor proportion score≥ 50%: randomized, double-blind phase III KEYNOTE-598 study M Boyer, MAN Şendur, D Rodríguez-Abreu, K Park, DH Lee, I Çiçin, ... Journal of clinical oncology 39 (21), 2327-2338, 2021 | 195 | 2021 |
| Pembrolizumab (pembro) plus axitinib (axi) versus sunitinib as first-line therapy for advanced clear cell renal cell carcinoma (ccRCC): Results from 42-month follow-up of … BI Rini, ER Plimack, V Stus, T Waddell, R Gafanov, F Pouliot, D Nosov, ... Journal of Clinical Oncology 39 (15_suppl), 4500-4500, 2021 | 130 | 2021 |
| Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for HER2-negative advanced gastric cancer (KEYNOTE-859): a multicentre, randomised, double-blind, phase 3 trial SY Rha, DY Oh, P Yañez, Y Bai, MH Ryu, J Lee, F Rivera, GV Alves, ... The Lancet Oncology 24 (11), 1181-1195, 2023 | 124 | 2023 |
| European experts consensus: BRCA/homologous recombination deficiency testing in first-line ovarian cancer I Vergote, A González-Martín, I Ray-Coquard, P Harter, N Colombo, ... Annals of Oncology 33 (3), 276-287, 2022 | 108 | 2022 |
| Dual PD-1 and CTLA-4 checkpoint blockade using balstilimab and zalifrelimab combination as second-line treatment for advanced cervical cancer: an open-label phase II study DM O'Malley, M Neffa, BJ Monk, T Melkadze, M Huang, A Kryzhanivska, ... Journal of clinical oncology 40 (7), 762-771, 2022 | 102 | 2022 |
| Randomized phase III ANGEL study of rivoceranib (apatinib)+ best supportive care (BSC) vs placebo+ BSC in patients with advanced/metastatic gastric cancer who failed≥ 2 prior … YK Kang, WK Kang, M Di Bartolomeo, I Chau, HH Yoon, S Cascinu, ... Annals of Oncology 30, v877-v878, 2019 | 69 | 2019 |
| A phase I, first-in-human, open-label, dose-escalation study of MGD013, a bispecific DART molecule binding PD-1 and LAG-3, in patients with unresectable or metastatic neoplasms JJ Luke, MR Patel, EP Hamilton, B Chmielowski, SV Ulahannan, ... J Clin Oncol 38 (15), 3004-3004, 2020 | 51 | 2020 |
| 2O IMpower010: Biomarkers of disease-free survival (DFS) in a phase III study of atezolizumab (atezo) vs best supportive care (BSC) after adjuvant chemotherapy in stage IB-IIIA … C Zhou, MD Thakur, MK Srivastava, W Zou, H Xu, M Ballinger, E Felip, ... Annals of Oncology 32, S1374, 2021 | 46 | 2021 |
| LBA34 Single-agent anti-PD-1 balstilimab or in combination with anti-CTLA-4 zalifrelimab for recurrent/metastatic (R/M) cervical cancer (CC): Preliminary results of two … DM O'Malley, A Oaknin, BJ Monk, A Leary, F Selle, J Alexandre, ... Annals of Oncology 31, S1164-S1165, 2020 | 45 | 2020 |
| Preliminary efficacy of durvalumab plus tremelimumab in platinum-refractory/resistant ED-SCLC from arm A of the phase II BALTIC study I Bondarenko, O Juan-Vidal, G Pajkos, A Kryzhanivska, ZP Székely, ... Annals of Oncology 29, viii596, 2018 | 35 | 2018 |
| Four-year overall survival update from the phase III HIMALAYA study of tremelimumab plus durvalumab in unresectable hepatocellular carcinoma B Sangro, SL Chan, RK Kelley, G Lau, M Kudo, W Sukeepaisarnjaroen, ... Annals of Oncology 35 (5), 448-457, 2024 | 30 | 2024 |
| Role of nitric oxide in pathogenesis of tumor growth and its possible application in cancer treatment VV Holotiuk, AY Kryzhanivsk, IK Churpiy, BB Tataryn, DY Ivasiutyn Experimental Oncology 41 (3), 210-215, 2019 | 28 | 2019 |
| Pembrolizumab (pembro) plus axitinib (axi) versus sunitinib as first-line therapy for locally advanced or metastatic renal cell carcinoma (mRCC): phase III KEYNOTE-426 study. T Powles, ER Plimack, V Stus, RA Gafanov, RE Hawkins, D Nosov, ... Journal of Clinical Oncology 37 (7_suppl), 543-543, 2019 | 22 | 2019 |
| Онкологія ГВ Бондар, ЮВ Думанський, ОЮ Попович, ІЄ Седаков, НГ Семикоз, ... ВСВ “Медицина”, 2013 | 19 | 2013 |
| Abstract CT178: Olaparib plus pembrolizumab in patients with previously treated advanced solid tumors with homologous recombination repair mutation (HRRm) and/or homologous … M Maio, R Shapira-Frommer, TA Yap, T Ciuleanu, H Gomez, A Hill, ... Cancer Research 81 (13_Supplement), CT178-CT178, 2021 | 15 | 2021 |
